News

Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.

The granted patent is broad in scope and covers both the formulation currently being used in the international clinical study STEP as well as future generations of products containing TCP-25.

TCP-25 is already protected by patents in Europe and the United States and has also been granted Orphan Drug Designation in the United States.

“A strong intellectual property position is essential for us, and this new patent provides broad protection in a strategically important market,” says Helene Hartman, CEO of Xinnate AB.

by Anna-Karin Lindqvist

Xinnate raises SEK 31 million in oversubscribed share issue

 Xinnate today announced successful closure of its share issue, raising 31 million in new capital for the development of TCP-25. The issue was oversubscribed demonstrating strong interest and confidence from both existing and new shareholders.

 - We extend our sincere thanks for our investors’ continued support, says CEO Helene Hartman. This marks a significant milestone accelerate the path to partnering, market and hence patients suffering from Epidermolysis Bullosa.

The funding enables us to move forward with our accelerated development strategy, following the transition to a CDMO partner with commercial manufacturing capacity. This includes:

• Advancing the pivotal STEP study for EB patients, backed by positive FDA feedback.
• Securing continued GMP manufacturing of clinical study material, following successful production of a pilot batch.
• Preparing for a potential commercial partnership and future NDA submission.

To accommodate those investors who were not allocated shares in this round, the Board plans to launch a directed issue during the summer.

by Anna-Karin Lindqvist

New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD

We are pleased to welcome Dr Per Norlén to Xinnate’s board of directors.

Dr Norlén brings over 20 years of experience in clinical drug development and leadership roles at AstraZeneca and several private and publicly listed biotechs, including Alligator Bioscience, Targinta, Evaxion Biotech, and WntResearch. He is currently the CEO of Strike Pharma.

His expertise will be invaluable as we advance our work developing innovative therapies for complex skin conditions and wounds.

by Anna-Karin Lindqvist